Pulse contour analysis-derived femoral dP/dtmax deviated from baseline by 21% (p=0.013) following dobutamine variations and 15% (p<0.001) following norepinephrine changes, demonstrating it is an unreliable estimate of left ventricular systolic function due to its sensitivity to afterload.
Observational (n=19)
Yes
Does pulse contour analysis-derived femoral dP/dtmax reliably estimate LV systolic function during changes in loading conditions in critically ill patients with cardiovascular failure?
Femoral dP/dtmax calculated by pulse contour analysis is an unreliable estimate of LV systolic function during changes in LV afterload and arterial load, as it is prominently influenced by arterial waveform characteristics.
Effect estimate: 21% deviation
p-value: p=0.013
Femoral dP/dtmax (maximum rate of the arterial pressure increase during systole) measured by pulse contour analysis has been proposed as a surrogate of left ventricular (LV) dP/dtmax and as an estimator of LV systolic function. However, femoral dP/dtmax may be influenced by LV loading conditions. In this study, we evaluated the impact of variations of LV systolic function, preload and afterload on femoral dP/dtmax in critically ill patients with cardiovascular failure to ascertain its reliability as a marker of LV systolic function. We performed a prospective observational study to evaluate changes in femoral dP/dtmax, thermodilution-derived variables (PiCCO2—Pulsion Medical Systems, Feldkirchen, Germany) and LV ejection fraction (LVEF) measured by transthoracic echocardiography during variations in dobutamine and norepinephrine doses and during volume expansion (VE) and passive leg raising (PLR). Correlations with arterial pulse and systolic pressure, effective arterial elastance, total arterial compliance and LVEF were also evaluated. In absolute values, femoral dP/dtmax deviated from baseline by 21% (201 ± 297 mmHg/s; p = 0.013) following variations in dobutamine dose (n = 17) and by 15% (177 ± 135 mmHg/s; p < 0.001) following norepinephrine dose changes (n = 29). Femoral dP/dtmax remained unchanged after VE and PLR (n = 24). Changes in femoral dP/dtmax were strongly correlated with changes in pulse pressure and systolic arterial pressure during dobutamine dose changes (R = 0.942 and 0.897, respectively), norepinephrine changes (R = 0.977 and 0.941, respectively) and VE or PLR (R = 0.924 and 0.897, respectively) (p < 0.05 in all cases). Changes in femoral dP/dtmax were correlated with changes in LVEF (R = 0.527) during dobutamine dose variations but also with effective arterial elastance and total arterial compliance in the norepinephrine group (R = 0.638 and R = − 0.689) (p < 0.05 in all cases). Pulse contour analysis-derived femoral dP/dtmax was not only influenced by LV systolic function but also and prominently by LV afterload and arterial waveform characteristics in patients with acute cardiovascular failure. These results suggest that femoral dP/dtmax calculated by pulse contour analysis is an unreliable estimate of LV systolic function during changes in LV afterload and arterial load by norepinephrine and directly linked to arterial waveform determinants.
Vaquer等(星期二)进行了一项针对急性心血管衰竭的观察性研究(n=19)。评估了血流动力学干预(多巴胺、去甲肾上腺素、容量扩张、被动抬腿)与基线(干预前)对股动脉dP/dtmax的绝对偏差,结果显示动态多巴胺剂量变化后偏差为21%(p=0.013)。经过多巴胺变化后,脉冲轮廓分析导出的股动脉dP/dtmax与基线偏差21%(p=0.013),去甲肾上腺素变化后的偏差为15%(p<0.001),显示其因对后负荷的敏感性而是不可靠的左心室收缩功能估计指标。
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: